O	0	9	Oncogenic	Oncogenic	JJ	B-NP
O	10	19	epidermal	epidermal	JJ	I-NP
O	20	26	growth	growth	NN	I-NP
O	27	33	factor	factor	NN	I-NP
O	34	42	receptor	receptor	NN	I-NP
O	43	50	mutants	mutant	NNS	I-NP
O	51	55	with	with	IN	B-PP
O	56	62	tandem	tandem	JJ	B-NP
O	63	74	duplication	duplication	NN	I-NP
O	74	75	:	:	:	O
O	76	80	gene	gene	NN	B-NP
O	81	90	structure	structure	NN	I-NP
O	91	94	and	and	CC	O
O	95	102	effects	effect	NNS	B-NP
O	103	105	on	on	IN	B-PP
O	106	114	receptor	receptor	NN	B-NP
O	115	123	function	function	NN	I-NP
O	123	124	.	.	.	O

O	126	127	A	A	DT	B-NP
O	128	134	number	number	NN	I-NP
O	135	137	of	of	IN	B-PP
O	138	147	epidermal	epidermal	JJ	B-NP
O	148	154	growth	growth	NN	I-NP
O	155	161	factor	factor	NN	I-NP
O	162	170	receptor	receptor	NN	I-NP
O	171	172	(	(	(	O
O	172	176	EGFR	EGFR	NN	B-NP
O	176	177	)	)	)	O
O	178	186	deletion	deletion	NN	B-NP
O	187	194	mutants	mutant	NNS	I-NP
O	195	199	have	have	VBP	B-VP
O	200	204	been	be	VBN	I-VP
O	205	215	identified	identify	VBN	I-VP
O	216	218	in	in	IN	B-PP
B-Cancer	219	226	gliomas	glioma	NNS	B-NP
O	226	227	,	,	,	O
O	228	230	in	in	IN	B-PP
O	231	236	which	which	WDT	B-NP
O	237	240	the	the	DT	B-NP
O	241	245	EGFR	EGFR	NN	I-NP
O	246	250	gene	gene	NN	I-NP
O	251	253	is	be	VBZ	B-VP
O	254	264	frequently	frequently	RB	I-VP
O	265	274	amplified	amplify	VBN	I-VP
O	275	278	and	and	CC	I-VP
O	279	289	rearranged	rearrange	VBN	I-VP
O	289	290	.	.	.	O

O	291	293	We	We	PRP	B-NP
O	294	298	have	have	VBP	B-VP
O	299	309	previously	previously	RB	I-VP
O	310	323	characterized	characterize	VBN	I-VP
O	324	327	the	the	DT	B-NP
O	328	337	structure	structure	NN	I-NP
O	338	340	of	of	IN	B-PP
O	341	342	a	a	DT	B-NP
O	343	347	gene	gene	NN	I-NP
O	348	350	in	in	IN	B-PP
B-Cell	351	352	A	A	NN	B-NP
I-Cell	352	353	-	-	HYPH	I-NP
I-Cell	353	356	172	172	CD	I-NP
I-Cell	357	362	human	human	JJ	I-NP
I-Cell	363	369	glioma	glioma	NN	I-NP
I-Cell	370	375	cells	cell	NNS	I-NP
O	376	380	that	that	WDT	B-NP
O	381	388	encodes	encode	VBZ	B-VP
O	389	390	a	a	DT	B-NP
O	391	394	190	190	CD	I-NP
O	394	395	-	-	HYPH	I-NP
O	395	398	kDa	kDa	NN	I-NP
O	399	403	EGFR	EGFR	NN	I-NP
O	404	410	mutant	mutant	NN	I-NP
O	411	415	with	with	IN	B-PP
O	416	422	tandem	tandem	JJ	B-NP
O	423	434	duplication	duplication	NN	I-NP
O	435	437	of	of	IN	B-PP
O	438	441	the	the	DT	B-NP
O	442	450	tyrosine	tyrosine	NN	I-NP
O	451	457	kinase	kinase	NN	I-NP
O	458	459	(	(	(	O
O	459	461	TK	TK	NN	B-NP
O	461	462	)	)	)	O
O	463	466	and	and	CC	O
O	467	474	calcium	calcium	NN	B-NP
O	474	475	-	-	HYPH	O
O	475	483	mediated	mediate	VBN	B-NP
O	484	499	internalization	internalization	NN	I-NP
O	500	501	(	(	(	O
O	501	505	CAIN	CAIN	NN	B-NP
O	505	506	)	)	)	O
O	507	514	domains	domain	NNS	B-NP
O	514	515	.	.	.	O

O	516	520	Here	Here	RB	B-ADVP
O	521	523	we	we	PRP	B-NP
O	524	532	describe	describe	VBP	B-VP
O	533	534	a	a	DT	B-NP
O	535	538	185	185	CD	I-NP
O	538	539	-	-	HYPH	I-NP
O	539	542	kDa	kDa	NN	I-NP
O	543	549	tandem	tandem	JJ	I-NP
O	550	561	duplication	duplication	NN	I-NP
O	562	568	mutant	mutant	NN	I-NP
O	569	570	(	(	(	O
O	570	573	TDM	TDM	NN	B-NP
O	573	574	)	)	)	O
O	575	579	that	that	WDT	B-NP
O	580	582	is	be	VBZ	B-VP
O	583	592	expressed	express	VBN	I-VP
O	593	595	in	in	IN	B-PP
B-Cell	596	598	KE	KE	NN	B-NP
O	599	602	and	and	CC	I-NP
B-Cell	603	604	A	A	NN	I-NP
I-Cell	604	605	-	-	HYPH	B-NP
I-Cell	605	609	1235	1235	CD	I-NP
I-Cell	610	616	glioma	glioma	NN	I-NP
I-Cell	617	622	cells	cell	NNS	I-NP
O	622	623	,	,	,	O
O	624	629	along	along	IN	B-PP
O	630	634	with	with	IN	B-PP
O	635	642	certain	certain	JJ	B-NP
O	643	653	functional	functional	JJ	I-NP
O	654	669	characteristics	characteristic	NNS	I-NP
O	670	672	of	of	IN	B-PP
O	673	676	the	the	DT	B-NP
O	677	684	mutants	mutant	NNS	I-NP
O	684	685	.	.	.	O

O	686	689	The	The	DT	B-NP
O	690	703	corresponding	correspond	VBG	I-NP
O	704	715	transcripts	transcript	NNS	I-NP
O	716	718	in	in	IN	B-PP
B-Cell	719	721	KE	KE	NN	B-NP
O	722	725	and	and	CC	I-NP
B-Cell	726	727	A	A	NN	I-NP
I-Cell	727	728	-	-	HYPH	O
I-Cell	728	732	1235	1235	CD	B-NP
I-Cell	733	738	cells	cell	NNS	I-NP
O	739	746	contain	contain	VBP	B-VP
O	747	751	1053	1053	CD	B-NP
O	752	762	additional	additional	JJ	I-NP
O	763	774	nucleotides	nucleotide	NNS	I-NP
O	775	787	representing	represent	VBG	B-VP
O	788	790	an	an	DT	B-NP
O	791	793	in	in	IN	B-PP
O	793	794	-	-	HYPH	B-NP
O	794	799	frame	frame	NN	I-NP
O	800	811	duplication	duplication	NN	I-NP
O	812	814	of	of	IN	B-PP
O	815	820	exons	exon	NNS	B-NP
O	821	823	18	18	CD	B-NP
O	824	831	through	through	IN	B-PP
O	832	834	25	25	CD	B-NP
O	835	840	which	which	WDT	B-NP
O	841	847	encode	encode	VBP	B-VP
O	848	851	the	the	DT	B-NP
O	852	858	entire	entire	JJ	I-NP
O	859	861	TK	TK	NN	I-NP
O	862	868	region	region	NN	I-NP
O	869	872	and	and	CC	O
O	873	874	a	a	DT	B-NP
O	875	882	portion	portion	NN	I-NP
O	883	885	of	of	IN	B-PP
O	886	889	the	the	DT	B-NP
O	890	894	CAIN	CAIN	NN	I-NP
O	895	901	domain	domain	NN	I-NP
O	901	902	.	.	.	O

O	903	905	As	As	IN	B-PP
O	906	910	with	with	IN	B-PP
O	911	922	duplication	duplication	NN	B-NP
O	923	925	of	of	IN	B-PP
O	926	929	the	the	DT	B-NP
O	930	936	entire	entire	JJ	I-NP
O	937	939	TK	TK	NN	I-NP
O	939	940	/	/	SYM	B-VP
O	940	944	CAIN	CAIN	NN	B-NP
O	945	951	region	region	NN	I-NP
O	952	953	(	(	(	O
O	953	958	exons	exon	NNS	B-NP
O	959	961	18	18	CD	B-NP
O	961	962	-	-	HYPH	B-NP
O	962	964	26	26	CD	I-NP
O	964	965	)	)	)	O
O	966	968	in	in	IN	B-PP
B-Cell	969	970	A	A	NN	B-NP
I-Cell	970	971	-	-	HYPH	I-NP
I-Cell	971	974	172	172	CD	I-NP
I-Cell	975	980	cells	cell	NNS	I-NP
O	980	981	,	,	,	O
O	982	993	duplication	duplication	NN	B-NP
O	994	996	of	of	IN	B-PP
O	997	1002	exons	exon	NNS	B-NP
O	1003	1005	18	18	CD	B-NP
O	1005	1006	-	-	HYPH	I-NP
O	1006	1008	25	25	CD	I-NP
O	1009	1011	is	be	VBZ	B-VP
O	1012	1022	associated	associate	VBN	I-VP
O	1023	1027	with	with	IN	B-PP
O	1028	1029	a	a	DT	B-NP
O	1030	1038	specific	specific	JJ	I-NP
O	1039	1046	genomic	genomic	JJ	I-NP
O	1047	1060	rearrangement	rearrangement	NN	I-NP
O	1061	1068	between	between	IN	B-PP
O	1069	1077	flanking	flank	VBG	B-NP
O	1078	1085	introns	intron	NNS	I-NP
O	1085	1086	.	.	.	O

O	1087	1095	Involved	Involve	VBN	B-NP
O	1096	1103	introns	intron	NNS	I-NP
O	1104	1111	contain	contain	VBP	B-VP
O	1112	1120	homology	homology	NN	B-NP
O	1121	1123	to	to	TO	B-PP
O	1124	1137	recombination	recombination	NN	B-NP
O	1138	1144	signal	signal	NN	I-NP
O	1145	1153	sequence	sequence	NN	I-NP
O	1154	1155	(	(	(	O
O	1155	1158	RSS	RSS	NN	B-NP
O	1158	1159	)	)	)	O
O	1160	1169	heptamers	heptamer	NNS	B-NP
O	1170	1177	present	present	JJ	B-ADJP
O	1178	1180	in	in	IN	B-PP
O	1181	1184	the	the	DT	B-NP
O	1185	1186	V	V	NN	I-NP
O	1186	1187	(	(	(	O
O	1187	1188	D	D	NN	B-NP
O	1188	1189	)	)	)	O
O	1189	1190	J	J	NN	B-NP
O	1191	1197	region	region	NN	I-NP
O	1198	1200	of	of	IN	B-PP
O	1201	1204	the	the	DT	B-NP
B-Cell	1205	1206	T	T	NN	I-NP
I-Cell	1207	1217	lymphocyte	lymphocyte	NN	I-NP
O	1218	1226	receptor	receptor	NN	I-NP
O	1227	1231	gene	gene	NN	I-NP
O	1231	1232	.	.	.	O

O	1233	1235	In	In	IN	B-PP
O	1236	1243	defined	define	VBN	B-NP
O	1244	1250	medium	medium	NN	I-NP
O	1250	1251	,	,	,	O
O	1252	1256	both	both	DT	B-NP
O	1257	1266	oncogenic	oncogenic	JJ	I-NP
O	1267	1270	TDM	TDM	NN	I-NP
O	1271	1274	are	be	VBP	B-VP
O	1275	1289	constitutively	constitutively	RB	I-VP
O	1290	1308	autophosphorylated	autophosphorylate	VBN	I-VP
O	1309	1312	and	and	CC	O
O	1313	1326	inefficiently	inefficiently	RB	B-VP
O	1327	1340	downregulated	downregulate	VBN	I-VP
O	1340	1341	.	.	.	O

O	1342	1346	High	High	JJ	B-NP
O	1346	1347	-	-	HYPH	I-NP
O	1347	1355	affinity	affinity	NN	I-NP
O	1356	1363	binding	binding	NN	I-NP
O	1364	1366	is	be	VBZ	B-VP
O	1367	1374	reduced	reduce	VBN	I-VP
O	1375	1377	in	in	IN	B-PP
O	1378	1382	EGFR	EGFR	NN	B-NP
O	1382	1383	.	.	SYM	I-NP
O	1383	1386	TDM	TDM	NN	I-NP
O	1386	1387	/	/	SYM	B-NP
O	1387	1389	18	18	CD	I-NP
O	1389	1390	-	-	HYPH	B-NP
O	1390	1392	26	26	CD	I-NP
O	1392	1393	,	,	,	O
O	1394	1402	although	although	IN	B-SBAR
O	1403	1406	the	the	DT	B-NP
O	1407	1409	t1	t1	NN	I-NP
O	1409	1410	/	/	SYM	O
O	1410	1411	2	2	CD	B-NP
O	1412	1414	of	of	IN	B-PP
O	1415	1423	receptor	receptor	NN	B-NP
O	1424	1439	internalization	internalization	NN	I-NP
O	1440	1442	is	be	VBZ	B-VP
O	1443	1446	not	not	RB	I-VP
O	1447	1456	prolonged	prolong	VBN	I-VP
O	1456	1457	.	.	.	O

